Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study
Background: Pre-clinical and clinical studies propose that statins may have chemopreventive effects against cancer, suggesting their possible roles as adjunctive therapies for melanoma. Objective: To investigate the association between regular statin use and disease recurrence in patients with resec...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824000016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846124911301492736 |
|---|---|
| author | Charlie Yue Wang Mark Shackleton Sonia Mailer Grant A. McArthur Sophia Zoungas Rory Wolfe Victoria J. Mar |
| author_facet | Charlie Yue Wang Mark Shackleton Sonia Mailer Grant A. McArthur Sophia Zoungas Rory Wolfe Victoria J. Mar |
| author_sort | Charlie Yue Wang |
| collection | DOAJ |
| description | Background: Pre-clinical and clinical studies propose that statins may have chemopreventive effects against cancer, suggesting their possible roles as adjunctive therapies for melanoma. Objective: To investigate the association between regular statin use and disease recurrence in patients with resected Stage I-III melanoma. Methods: We conducted a retrospective analysis of patients enrolled in the multi-center Melanoma Research Victoria cohort with a histologically confirmed, resected American Joint Committee on Cancer Stage I-III cutaneous melanoma. Patients with uveal melanoma, melanoma of unknown primary site, or mucosal melanoma were excluded. Melanoma recurrence outcomes were compared between statin users and statin non-users, with statin use determined by linkage to the Pharmaceutical Benefits Scheme (Australia) prescription database. Results: 624 patients with resected Stage I-III melanoma at diagnosis were eligible for the study. 193 patients were classified as statin users and 431 patients as statin non-users. In all, 45 statin users experienced disease recurrence compared to 140 (23.3 vs 32.5%, p = 0.05) statin non-users with similar durations of follow-up (median 2.2 and 2.4 years, respectively). After adjustment, statin users had a lower risk melanoma recurrence than statin non-users (HR 0.66, 95%CI 0.44–0.99, p = 0.04). A lower risk of recurrence was also observed in subset analyzes of statin users on high-dose therapy (HR 0.50, 95%CI 0.25–0.99, p = 0.05) and patients who were adherent to statin therapy (HR 0.60, 95%CI 0.39–0.92, p = 0.02). Conclusion: Our study supports the possibility that an association exists between statin use and reduced disease recurrence in resected cutaneous melanoma. |
| format | Article |
| id | doaj-art-b242ae85c640433bbb6a4f9fde3aafbf |
| institution | Kabale University |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-b242ae85c640433bbb6a4f9fde3aafbf2024-12-13T11:08:35ZengElsevierEJC Skin Cancer2772-61182024-12-012100017Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort studyCharlie Yue Wang0Mark Shackleton1Sonia Mailer2Grant A. McArthur3Sophia Zoungas4Rory Wolfe5Victoria J. Mar6Victorian Melanoma Service, The Alfred Hospital, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Correspondence to: Victorian Melanoma Service, The Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004, Australia.Department of Oncology, Alfred Health, Prahran, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, AustraliaCancer Research Division and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaCancer Research Division and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, AustraliaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaVictorian Melanoma Service, The Alfred Hospital, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaBackground: Pre-clinical and clinical studies propose that statins may have chemopreventive effects against cancer, suggesting their possible roles as adjunctive therapies for melanoma. Objective: To investigate the association between regular statin use and disease recurrence in patients with resected Stage I-III melanoma. Methods: We conducted a retrospective analysis of patients enrolled in the multi-center Melanoma Research Victoria cohort with a histologically confirmed, resected American Joint Committee on Cancer Stage I-III cutaneous melanoma. Patients with uveal melanoma, melanoma of unknown primary site, or mucosal melanoma were excluded. Melanoma recurrence outcomes were compared between statin users and statin non-users, with statin use determined by linkage to the Pharmaceutical Benefits Scheme (Australia) prescription database. Results: 624 patients with resected Stage I-III melanoma at diagnosis were eligible for the study. 193 patients were classified as statin users and 431 patients as statin non-users. In all, 45 statin users experienced disease recurrence compared to 140 (23.3 vs 32.5%, p = 0.05) statin non-users with similar durations of follow-up (median 2.2 and 2.4 years, respectively). After adjustment, statin users had a lower risk melanoma recurrence than statin non-users (HR 0.66, 95%CI 0.44–0.99, p = 0.04). A lower risk of recurrence was also observed in subset analyzes of statin users on high-dose therapy (HR 0.50, 95%CI 0.25–0.99, p = 0.05) and patients who were adherent to statin therapy (HR 0.60, 95%CI 0.39–0.92, p = 0.02). Conclusion: Our study supports the possibility that an association exists between statin use and reduced disease recurrence in resected cutaneous melanoma.http://www.sciencedirect.com/science/article/pii/S2772611824000016MelanomaStatinImmune Checkpoint InhibitorsDrug RepositioningAdjuvant Drug Therapy |
| spellingShingle | Charlie Yue Wang Mark Shackleton Sonia Mailer Grant A. McArthur Sophia Zoungas Rory Wolfe Victoria J. Mar Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study EJC Skin Cancer Melanoma Statin Immune Checkpoint Inhibitors Drug Repositioning Adjuvant Drug Therapy |
| title | Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study |
| title_full | Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study |
| title_fullStr | Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study |
| title_full_unstemmed | Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study |
| title_short | Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study |
| title_sort | statin use in resected high risk cutaneous melanoma a multi centre retrospective cohort study |
| topic | Melanoma Statin Immune Checkpoint Inhibitors Drug Repositioning Adjuvant Drug Therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824000016 |
| work_keys_str_mv | AT charlieyuewang statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT markshackleton statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT soniamailer statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT grantamcarthur statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT sophiazoungas statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT rorywolfe statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy AT victoriajmar statinuseinresectedhighriskcutaneousmelanomaamulticentreretrospectivecohortstudy |